SCHEMBL4040956

SCHEMBL4040956

COc1ccc(-c2cc(=S)c3cccc(C)c3o2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.64
CYP1A1 P04798 6/20 0.55
CYP1B1 Q16678 6/20 0.55
CYP1A2 P05177 5/20 0.55
ABCB1 P08183 1/20 0.48
ABCC1 P33527 1/20 0.48
ABCG2 Q9UNQ0 1/20 0.48
KDM4E B2RXH2 3/20 0.47
MAPT P10636 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
LMNA P02545 2/20 0.47
NPC1 O15118 1/20 0.47
TNKS O95271 1/20 0.47
TP53 P04637 1/20 0.47
GLA P06280 1/20 0.47
CYP3A4 P08684 1/20 0.47
THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL535362 0.83 CYP1A1 (0.68) MAOBCYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL4041393 0.80 MAPT (0.51) MAOBCYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL13797838 0.80 MAPT (0.51) MAOBCYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL4041398 0.80 MAPT (0.51) MAOBCYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL24533215 0.72 ALDH1A1 (0.44) MAOBCYP1A1CYP1B1CYP1A2KDM4E
SCHEMBL1742227 0.70 CYP1A1 (0.73) MAOBCYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL13990268 0.69 EGFR (0.65) MAOBABCB1ABCG2KDM4EMAPT
SCHEMBL21801178 0.69 CYP1A1 (0.67) MAOBCYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL9550456 0.67 NTRK1 (0.56) MAOBCYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL14266179 0.67 ALDH1A1 (0.59) KDM4EMAPTALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547794-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-16 US disclosed
EP-1615906-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2006-01-18 EP disclosed
WO-2004092154-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-10-28 WO disclosed
US-20040198750-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198750-A1 Compositions useful as inhibitors of protein kinases MAP3K20, MAP3K6, PACSIN2 MAOB 3049/4885CYP1A1 4827/4885CYP1B1 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.